The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at an assay dependent dilution.
WB: Use at a concentration of 1 - 5 µg/ml. Predicted molecular weight: 153 kDa.
This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceKIAA1199 belongs to the TMEM2 family and contains 4 PbH1 repeats. It is expressed in the inner ear. It is expressed in cochlea and vestibule tissues and it may be involved in hearing. Defects in KIAA1199 may be a cause of non-syndromic hearing loss. It is also thought that KIAA1199 is a tumor suppressor that may be involved in establishing cellular mortality in normal human cells.
Jia S et al. KIAA1199 promotes migration and invasion by Wnt/ß-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer. PLoS One12:e0175058 (2017).
Read more (PubMed: 28422983) »